Clopidogrel and CYP2C19: Pharmacogenetic Testing Ready for Clinical Prime Time?
Clinical Chemistry Podcast · Association for Diagnostics and Laboratory Medicine
October 8, 201511m 11s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
For patients with acute coronary syndrome who have undergone interventions such as placement of a stent, it has become standard practice to treat them with a combination of aspirin and opidogrel to prevent subsequent thrombotic events; however, clopidogrel is a drug that requires activation by a liver enzyme, CYP2C19.